Shots:

• The (D7220C00001) trial evaluates Vaxzevria in patients with COVID-19 which showed that Vaxzevria increased the immune response to Beta, Delta, Alpha & Gamma SARS-CoV-2 variants given as a 3rd dose booster in the preliminary analysis & was well tolerated while an additional analysis showed increased Ab response to the Omicron variant
• The P-IV trial showed that the 3rd dose of Vaxzevria has increased Ab levels, based on the primary vaccine of CoronaVac
• The additional analyses from the D7220C00001 trial are expected in H1’22. Following a sub-license agreement with AstraZeneca, the vaccine is manufactured & supplied by the Serum Institute of India under the brand name Covishield

Ref: AstraZeneca | Image: Al Jazeera